reports
Resmed Announces Participation in the 44th Annual J.P. Morgan Healthca...
Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay...
Edwards Lifesciences Corp: 3 directors
Three Directors at Edwards Lifesciences Corp sold/sold after exercising options/gave away 22,120 shares at between 0.000USD and 84.029USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretion...
Stryker declares an $0.88 per share quarterly dividend
Stryker declares an $0.88 per share quarterly dividend Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter. “We remain confident in our ability to deliver strong financial performance, and consistent with our capital allocation priorities we are increasing our dividend to $0.88 per share,” said Kevin Lobo...
Resmed Receives FDA Clearance for Personalized Therapy Comfort Setting...
Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy Technology uses real-world sleep data and machine learning to help people with sleep apnea start and stay on therapy SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has received U.S. Food and Drug Administration (FDA) clearance for Personalized Therapy Comfort Setting...
Stryker names Spencer Stiles President and Chief Operating Officer
Stryker names Spencer Stiles President and Chief Operating Officer Dylan Crotty promoted to Group President, Orthopaedics Portage, Michighan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today Spencer Stiles has been appointed President and Chief Operating Officer (COO), effective January 1, 2026. In this role, Stiles will lead the company’s global businesses, strategy, and mergers and acquisitions. “Appointing Spencer President and COO strengthens our ability to sustain high growth and leverage the breadth of our portfolio,” ...
Johnson & Johnson: 1 director
A director at Johnson & Johnson bought 1,250 shares at 206.150USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
ResMed Inc: 1 director
A director at ResMed Inc sold/sold after exercising options 2,055 shares at 255.000USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
Medtronic Plc: 1 director
A director at Medtronic Plc sold 30,000 shares at 101.948USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Steris Plc: 1 director
A director at Steris Plc sold/sold after exercising options 5,036 shares at 257.554USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...
Stryker Corp: 1 director
A director at Stryker Corp sold 520,000 shares at 355.012USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Boston Scientific Corp: 1 director
A director at Boston Scientific Corp sold 12,891 shares at 98.284USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Stryker reports third quarter 2025 operating results
Stryker reports third quarter 2025 operating results Portage, Michigan, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2025: Third Quarter Results Reported net sales increased 10.3% to $6.1 billionOrganic net sales increased 9.5%Reported operating income margin of 18.7%Adjusted operating income margin(1) increased 90 bps to 25.6%Reported EPS increased 2.8% to $2.22Adjusted EPS(1) increased 11.1% to $3.19 Third Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures Organ...
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 202...
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026 Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0%Income from operations increased 15%; non-GAAP income from operations up 19%Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55Operating cash flow of $457 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) to...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.